Early-onset severe spinocerebellar ataxia 42 with neurodevelopmental deficits (SCA42ND): Case report, pharmacological trial, and literature review.

MLA

Casas-Alba, Dídac, et al. “Early-Onset Severe Spinocerebellar Ataxia 42 with Neurodevelopmental Deficits (SCA42ND): Case Report, Pharmacological Trial, and Literature Review.” American Journal of Medical Genetics. Part A, vol. 185, no. 1, Jan. 2021, pp. 256–60. EBSCOhost, https://doi.org/10.1002/ajmg.a.61939.

APA

Casas-Alba, D., López-Sala, L., Pérez-Ordóñez, M., Mari-Vico, R., Bolasell, M., Martínez-Monseny, A. F., Muchart, J., Fernández-Fernández, J. M., Martorell, L., & Serrano, M. (2021). Early-onset severe spinocerebellar ataxia 42 with neurodevelopmental deficits (SCA42ND): Case report, pharmacological trial, and literature review. American Journal of Medical Genetics. Part A, 185(1), 256–260. https://doi.org/10.1002/ajmg.a.61939

Chicago

Casas-Alba, Dídac, Laura López-Sala, Marta Pérez-Ordóñez, Rosanna Mari-Vico, Mercè Bolasell, Antonio F Martínez-Monseny, Jordi Muchart, José M Fernández-Fernández, Loreto Martorell, and Mercedes Serrano. 2021. “Early-Onset Severe Spinocerebellar Ataxia 42 with Neurodevelopmental Deficits (SCA42ND): Case Report, Pharmacological Trial, and Literature Review.” American Journal of Medical Genetics. Part A 185 (1): 256–60. doi:10.1002/ajmg.a.61939.